BioFlex has been cleared by the FDA, Health Canada. The CE mark of approval has also been obtained and the manufacturing standards of UL and ISO have been met.

Most forms of treatment including acupuncture, massage, ultrasound, medication, TENS, etc. have been used to treat pain and stimulate the healing processes. For the most part the effects of these treatments have been discouraging or provide only temporary relief as they do little more then mask the symptoms. Alleviating symptoms has generally and unfortunately become the accepted norm of treating most conditions.

Super luminous diodes (SLD) are designed for the treatment of a large surface area. These are less powerful than laser diodes and can be safely applied in larger numbers over a wide area. Laser diodes (LD) have higher power output and narrow beams, making them ideally suited as "laser probes" for deeper penetration and for targeting localized areas.

Registration for Phoslock has been obtained under the National Industrial Chemical Notification and Assessment Scheme (NICNAS) for commercial use in water treatment in Australia. The US EPA has issued a Pre Manufacture Notice for Phoslock. All toxicity tests that have been completed in Australia for NICNAS registration have conformed to the same toxicity characterization leachate protocol (TCLP) that is used in the US as well as many other countries.

Yes, Met-Tile's fire retardancy and wind resistance are recognized by the Council of American Building Officials, its regional member groups, and other local authorities. Evaluation reports are available on request.

You will want to make sure that your type of business is a permitted "use" for its location under the zoning laws of the municipality. Several other regulatory approvals may be necessary, depending on the nature of the business.

The BioFlex system offers a variety of patented, flexible, multi-source diode array treatment heads that can be contoured to many different parts of the body. This enables maximum coverage and contact facilitating optimal absorption by the cells in the treated area. The BioFlex system allows for greater versatility, control and accuracy. The patented PC Based operating software provided with the BioFlex system comes equipped with experience-based protocols.

BioFlex is a highly sophisticated therapeutic modality that combines the potential benefits of low intensity laser with super luminous diodes for the effective treatment of many medical disorders. Developed and engineered by Meditech International Incorporated, BioFlex represents the decade's most significant technological advancement in laser therapy.

For many years, rehabilitation therapies -- including ultrasound, interferential current and TENS -- have been used extensively throughout the world to treat pain and stimulate the healing processes. Unlike BioFlex, however, the healing effects of these treatments have been disappointing as they only modulate symptoms. In contrast BioFlex is able to influence the pathology directly at the cellular level, resulting in therapeutic benefits that are more profound and generally curative.

This?data sheet pertains to the U.S. Federal Food and Drug Administration (FDA) regulations governing the use of fluoroadditives as articles or components of articles intended for use in contact with food.

CE is the European Standard that controls Medical Devices. Specs2go's main supplier is CE Class 2 approved.

CE is the European Standard that controls Medical Devices. Best4Glasses's main supplier is CE Class 2 approved.

Many of its uses are US EPA, FDA, and UK Government approved, and highly recommended by many researchers and research establishments throughout the world...more

PainBan??? X4000 has undergone extensive clinical trials and is certified as a class 1 medical device according to the EC council Directive 93/42/EEC. MHRA approval is pending. The product is also protected under Patent Application IE/04/00098. PainBan??? X4000 has also been approved for use by the Complementary Medical Association for general pain management and in conjunction with acupuncture, acupressure and physiotherapy. Tens of thousands of patients have been treated successfully.

The HeartMate systems have been approved by the FDA for commercial sale in the U.S. for use as a "bridge to transplant", to keep critically ill people alive until donor hearts become available. The electric HeartMate system was approved in 1998. Patients with the electric system can be discharged from the hospital to live at home while awaiting a donor heart. To date, the electric HeartMate device has supported patients for as long as three years. In the U.S.

Zurn corrosive waste drainage system complies with ASTM-F1412 "Standard Specification for Polyolefin Pipe and Fittings for Corrosive Waste Drainage Systems" and is listed with or meets requirements of NSF, IAPMO, CSA B181.3.

Our regulatory expertise is a primary reason for our ability to bring products to market quickly and efficiently. Having brought several innovative drugs through the complex regulatory process, we have a commanding knowledge of relevant laws and regulations regarding Investigational New Drug/New Drug Applications (IND/NDA) and Quality Assurance/Quality Control (QA/QC) processes. Our track record includes meeting the requirements of the expedited review process for drugs such as Namenda.

Size of Treatment Arrays: BioFlex treatment arrays are flexible and cover a wide area (12.5 sq inches); this enables increased contact between the treatment array and tissues, maximizing therapy to the region being treated. More focused treatment is then carried out using the laser probe directly over the focus of the pathology.

T‑SPOT.TB carries the CE mark which allows it to be legally placed on the market to be sold freely in the EU. Approvals have already been achieved in a number of territories outside the EU and approval is being sought in the remaining territories of commercial interest to the company. The assay was designed and developed following design controls as specified in ISO 13485:2003, for which standard the company is certified. The company is also certified to ISO 9001:2000.

BioFlex is recommended as the treatment of choice for sufferers of musculoskeletal conditions in rehabilitation, physiotherapy and sports medicine. Specifically, it can effectively treat many medical conditions, including acute injuries, degenerative disorders and wound healing.

Unlike many pharmaceutical options, BioFlex is non toxic; unlike surgical procedures, it is non-traumatic and most important, BioFlex is non-invasive.

Regulators increasingly look to Financial Planners Standards Council to help them with their dual mandate of instilling public confidence in the financial markets and of protecting the public from being victimized by unscrupulous and unqualified intermediaries.

every review and project is unique and many variations exist, other government agencies may need to review and approve your project. The Division of Compliance will inform you of these additional reviews or approvals at the time plans are submitted.

GS2s are certified CSA for Canada and the U.S. They are certified Class I, Division 2, Groups A, B, C, and D.

Several controlled studies have been conducted since 1996 using the BioFlex Professional System. Two of these involved experimental models of Delayed Onset Muscle Soreness (DOMS) and Rheumatoid Arthritis. The results of both studies showed BioFlex producing significant, positive effects on these disorders. A synopsis of these studies is available. Meditech has embarked on an extensive program of Beta Testing of the BioFlex user protocols.